Jazz Pharmaceuticals to Acquire Chimerix for $935 Million, Gaining Promising Brain Tumor Drug Dordaviprone on March 05, 2025 Acquisition Approved Brain Neoplasms Chimerix Diffuse Glioma Dordaviprone Jazz oncology pipeline United States Food and Drug Administration +